Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

27. Februar 2024 07:58 ET | Quelle: Clearmind Medicine Inc.

Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds

New patent applications build upon Clearmind’s broad IP protection in the psychedelic space Vancouver, Canada, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE:...
27. Februar 2024 07:58 ET | Quelle: SciSparc Ltd

SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds

TEL AVIV, Israel, Feb. 27, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies...
22. Februar 2023 08:00 ET | Quelle: SciSparc Ltd

SciSparc and Clearmind Reveal Three Unique Combinations of Future Psychedelic-Based Compounds

Tel Aviv, Israel, Feb. 22, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of...
22. Februar 2023 08:00 ET | Quelle: Clearmind Medicine Inc.

Israel-Based Clearmind Medicine Files Patent Applications for Three Unique Combinations of Future Psychedelic-Based Compounds

The company submitted three provisional patent applications with the United States Patent and Trademark Office to protect the novel combination compounds with SciSparc's PEA Tel Aviv, Israel /...